Improved risk prediction of chemotherapy‐induced neutropenia—model development and validation with real‐world data
Abstract Background The existing risk prediction models for chemotherapy‐induced febrile neutropenia (FN) do not necessarily apply to real‐life patients in different healthcare systems and the external validation of these models are often lacking. Our study evaluates whether a machine learning‐based...
Main Authors: | Mikko S. Venäläinen, Eetu Heervä, Outi Hirvonen, Sohrab Saraei, Tomi Suomi, Toni Mikkola, Maarit Bärlund, Sirkku Jyrkkiö, Tarja Laitinen, Laura L. Elo |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-02-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.4465 |
Similar Items
-
Chemotherapy limiting neutropenia. Is prevention required?
by: I. B. Kononenko, et al.
Published: (2022-01-01) -
The frequency of regimens associated with high risk of febrile neutropenia and the incidence of dose-limiting neutropenia among patients receiving cytotoxic therapy for malignancies: the FLAME study results
by: Anton V. Snegovoy, et al.
Published: (2023-12-01) -
Neutropenia in pediatric hematology/oncology practice
by: E. A. Deordieva, et al.
Published: (2015-06-01) -
Neutropenia in pediatric hematology/oncology practice
by: E. A. Deordieva, et al.
Published: (2015-06-01) -
Role of biosimilars in neutropenia prevention in cancer patients
by: V. V. Ptushkin
Published: (2015-01-01)